Pathological Results of Aggressive Hepatocellular Carcinomas Treated Using SIRT

Pathological Results After Downstaging of Agressive Hepatocellular Carcinoma Using 90Y-SIRT With Personalized Dosimetry

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05045573

Acronym

PAHCHS

Enrollment

Registered

2021-09-16

Start date

2014-01-01

Completion date

2021-08-30

Last updated

2021-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Brief summary

The aim of our study is to analyze pathological analysis of surgically treated aggressive hepatocellular carcinomas after radio-embolization. The investigators aim to demonstrate that a higher dose results in better tumor response while respecting safety conditions, that is, no radiologically induced liver disease.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

\- aggressive hepatocellular carcinomas with vascular invasion, large tumors or multifocal distribution

Exclusion criteria

* Other treatment after SIRT (confounding effect) * contraindications for surgery

Design outcomes

Primary

Measure	Time frame	Description
Pathological tumor response	6 months	Patients are treated with SIRT, then if the tumor response was adequate, surgery was performed.Analysis after surgery. (6 months after SIRT)

Secondary

Measure	Time frame	Description
Rate of Healthy liver hypertrophia	day 1	Rate of Healthy liver hypertrophia

Countries

France

Outcome results